tradmap

FENC FENNEC PHARMACEUTICALS INC.

$9.05 +0.95%

Healthcare · Biological Products, (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC. (FENC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry. Shares last traded at $9.05, 17.7% below their 52-week high. Over the past year the stock is up 18.0%. Net profit margin is -21820.3%, below the peer median of 6.3%. Revenue declined 6.1% year over year.

Market Cap
Shares Out
EPS (TTM)
$-0.37
P/E Ratio
P/S Ratio
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$10.99
52-Week Low
$5.66
Volume
11,051
Avg Vol (3m)
12,355.937

Performance

1W
+2.49%
1M
-7.08%
3M
+18.46%
6M
+18.61%
YTD
+17.53%
1Y
+17.99%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.33
SMA (50)
$8.01
SMA (200)
$8.03
Price vs SMA50
+13.05%
Price vs SMA200
+12.69%
ATR (14)
$0.59

Financials

Revenue
$45M
Net Income
$-9741M
Gross Margin
44.8%
Operating Margin
-14.1%
Net Margin
-21820.3%
Return on Equity
-25855.3%
Return on Assets
-13562.7%
Current Ratio
6.98
Debt / Equity
0.51
Revenue Growth (YoY)
-6.1%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $0.01 2026-05-14
FY 2025 $-0.34 2026-03-27
Q3 2025 $-0.18 2025-11-13
Q2 2025 $-0.16 2025-08-14
Q1 2026 $-0.04 2026-05-14
FY 2025 $-0.02 2026-03-27

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

FENC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.